Galiximab clinical trials
Also written IDEC-114.
How each study uses galiximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses galiximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00516217Written as galiximab
- Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00117975Written as galiximab
- Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 3BiogenNCT00384150Written as galiximab in combination with rituximab
- A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 3BiogenNCT00363636Written as Galiximab in combination with rituximab
- Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's LymphomaCompletedPhase 1/2BiogenNCT00048555Written as IDEC-114
- Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's LymphomaCompletedPhase 1/2BiogenNCT00575068Written as IDEC-114
- Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's LymphomaTerminatedPhase 1BiogenNCT00651443Written as Galiximab
Codes
What other systems call galiximab · ClinicalTrials.gg INT004386
- MeSH (NLM) C437823galiximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S9OX9692ZBGALIXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q966412galiximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C26447GaliximabOne source FDA
- DrugBank DB04901One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C437823 | galiximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S9OX9692ZB | GALIXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q966412 | galiximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C26447 | Galiximab | One source FDA |
| DrugBank | DB04901 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.